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Preamble
In every health system, pharmacotherapy con-
stitutes a basic therapeutic method that is presently
advocated not just by physicians, as it used to be, but
also by other members of the medical profession.
However, it is the pharmacist that possesses complex
knowledge not only of the medication effects mech-
anism and its activity in the organism, but also of the
factors which ensure its quality and stability in the
environment in which it is applied. Modern society
expects pharmacists to be more involved in monitor-
ing and supervising pharmacotherapy. International
documents clearly define pharmacists as guardians
of the safety and effectiveness of pharmacotherapy,
not coincidentally putting safety matters first. In
todayís era of specialized physicians, there is a
strong need for a greater role to be played by phar-
macists, whose knowledge covers many aspects con-
nected with pharmacodynamics, pharmacokinetics
and physicochemical medication properties ñ every-
thing, which influences the therapeutic process.
Since public trust professions in accordance
with the role attributed to them guard the public inter-
est, placing the good of society and its individual
units over the interests of their own group, it is impor-
tant to identify a method which ensures that this aim
will be fulfilled. The prestige of the profession is not
simply the sum of the prestige of its individual repre-
sentatives as the incorrect or, even worse, unethical
actions of a small group of the professionís represen-
tatives may seriously undermine the positive view of
the whole professional group in the society.
The significant and exceptionally fast changes
that are currently taking place in pharmaceutical sci-
ences indicate that the role of pharmacists is no longer
limited to the distribution of medicinal products but
also includes enabling members of society to fully take
advantage of the achievements of modern pharmacy.
Pharmacists offer a service to patients as well as advice
to physicians and other members of the medical pro-
fession, so they must be considered a full member of
the health team, contributing their unique knowledge
of active substances and medicinal products.
With regard to the above, the National Section
of Pharmaceutical Care of the Polish Pharmaceutical
Society presents its own proposal for the develop-
ment of modern pharmaceutical practice in Poland.
The purpose of the proposed actions is to increase
the involvement of pharmacists from community
pharmacies in ensuring the safety and effectiveness
of pharmacotherapy applied outside of hospitals and
improving indicators of societyís health over the
next ten to twenty nearest years.
Part I. Programme for developing pharmaceuti-
cal practice in generally accessible pharmacies
The role of pharmacists in a health care system
is not simply limited to dispensing medications and
ensuring they are of sufficient quality. International
pharmaceutical organizations have stressed for many
years that it is essential to involve pharmacists in
monitoring the use of medications by patients and
health system personnel. It is every countryís respon-
sibility to formulate its own pharmacy development
programme to ensure that pharmacists take at least
partial responsibility for the safety and effectiveness
of pharmacotherapy. Every society has to design its
own service system in community pharmacies. In
doing so, it is useful to draw lessons from the experi-
ence of countries in which additional pharmaceutical
services have been provided over many years, and
then adapt and adjust them to the conditions of oneís
own health system. Part I of this document therefore
presents an overview of services considered in devel-
oped countries to be effective in monitoring the use of
medicinal products in society. Implementing these
services in community pharmacies in Poland would
require pharmacists to take partial responsibility for
the correct use of medications among patients.
For every service, the purpose of its provision
and the tasks required for pharmacy personnel are
presented and, in selected cases, groups of patients
to which the service should be directed in the first
place are proposed. Such specifically indicated
groups include, inter alia:
 the geriatric population;
 the pediatric population (through cooperation
with parents and caregivers);
 patients under polytherapy;
 patients suffering from organ failure in connec-
tion with the metabolism process and drug excre-
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tion ñ e.g., renal failure, liver diseases, damaged
gastrointestinal tract;
 people with historical or current addictions to
medications, alcohol, or drugs;
 people with physical and/or psychical limitations
which may influence therapy ñ e.g.,
 people who are blind, deaf, suffer from
perception disorders, e.g., color recogni-
tion disorders, or people with neoplastic
diseases;
 pregnant and breastfeeding women.
I.1. Medication reviews
A medication review (MR) is a task that
requires the professional competencies of a pharma-
cist in order to be undertaken. It is performed on the
basis of data collected from a patient and constitutes
grounds for assessing the correctness of an ill per-
sonís medication use. It consists of the following
stages: (a) conducting a patient interview, (b) ana-
lyzing information collected from the patient, (c)
preparing a report for a physician, (d) preparing a
report for the patient, (e) establishing a programme
Table 1. Stages of Medical Utilization Review.
Purpose: collecting information on a patientís medication use.
Description of procedure: the pharmacist should collect information on all medications used by the
patient in accordance with the following criteria:
Medications prescribed by a physician:
the trade name of the medication, dosage, form, amount possessed, how it is used (what dosage, how
many times daily), who prescribed the medicine (name, surname, specialization), how to prepare before
administering (if necessary), storage, purpose of use for the patient, have there been any problems when
using it, were there any adverse effects, does the patient use the medication regularly, and did the patient
decide not to buy the medication for e.g., financial reasons?
Medications sold without prescription:
the trade name of the medication, dosage, form, amount currently in home medicine cabinet, how it is
used (how many dosages at one time/daily/time intervals), how often the patient takes the medication,
how to prepare it before administering (if necessary), storage, purpose of use for the patient, is there a
need to use it, have there been any problems when using it, were there any adverse effects? 
Supplements: medical products, dietary supplements:
the trade name, dosage, form, amount currently in home medicine cabinet, how used (how many
dosages at one time/daily/time interval), how often used, how to prepare it before administering (if nec-
essary), storage, the purpose of use of medication/medical product/dietary supplement, is there a need
to use the medical product/dietary supplement, who suggested the medication/medical product/dietary
supplement, have there been any problems when using it, were there any adverse effects?  
Purpose: detecting drug related problems, assessment of suitability of medication and its correct use.
Description of procedure: for every medication the pharmacist assesses: have any (real) drug related
problems appeared; is there a risk that (potential) drug related problems will emerge in the future; is
there a better (newer generation/more cost-effective) medication on the market that should replace the
one used by patient? Note: in accordance with the adopted classification of drug related problems, it is
necessary to mention any potential additional advice outside the scope of the adopted classification
which may have an influence on medication use. In assessing drug related problems, one should take
note of the influence of dietary supplements used by patient on the safety and effectiveness of pharma-
cotherapy.  
Purpose: informing a physician about the patientís medication use and detected drug related problems
in order to simplify future therapy.
Description: a report containing data on actual medication use by the ill person, detected drug related
problems (real and potential), suggested changes (according to the adopted guidelines for the proce-
dure), information on reimbursement rules for each medication, and information on the possible lack of
dispensing due to patientís decision to not purchase.  
Purpose: explaining to the patient how each medication should be used.
Description of procedure: a report including instructions on how the medication should be prepared
before use (if necessary), information concerning medication use, a medication use calendar, any detect-
ed improper medication use, date of next medication review.  
Purpose: determining the necessity for conducting the next medication utilization review.
Description of procedure: if a large number of drug related problems was detected and it is deemed that
managing them may be hard for patient, it is necessary to establish a date for the next meeting with the
patient, which would help determine whether the plan of action was implemented correctly.
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of correct medication use. Table 1 is documenting
the purpose of each stage accompanied by a descrip-
tion of the relevant procedure.
I.2. Systems of individual medication packaging
The problem of patientís lack of cooperation and
nonadherence (noncompliance) is presently one of the
most often mentioned drug related problems occurring
in civilized societies, and the commonly used poly-
therapy increases its risk. The marketing authorization
holder introduces medications to the market in indi-
vidual packaging, usually containing the amount of
doses which is necessary for a complete treatment
course (e.g., in antibiotic therapy) or a treatment over
a specified time interval (in the case of medications
used over a longer time). However, in the case of most
medications, the Summaries of Product Characteristic
(SPC) specify various indications for its use and, in
relation to them, often different doses to take at one
time, which results in the full packaging being insuffi-
cient for the treatment designed for the ill person or
specifying a dosage which exceeds the necessary
amount. Introducing a system of individual medica-
tion packaging enables a medication to be repackaged
and it to be dispensed in the amount which is appro-
priate for the treatment time specified by the pre-
scriber. There are various forms of individual medica-
tion dispensation available:
1. dispensing every product in separate individual
packaging, without dividing them into doses to
take at one time - the patient receives a medica-
tion for e.g., 30 days of treatment, and the pack-
aging is supplied with information on the pre-
scribed dosage programme together with dates
for beginning and ending the therapy;
2. dispensing all medication in collective packag-
ing divided into daily doses, each of which
comes with information on the day and hour of
administration;
3. the patient receives all medication prescribed
for use in collective packaging (multipack) with
information on specific days and hours of
administration.
Systems of individual medication packaging
(SIMP) enable the preparation of medications for
direct administration by patients. A pharmacy may
apply a system of manual or automatic medications
repackaging. It is possible to introduce a system of
unit doses, particularly for specific groups of
patients, e.g., elderly people, those using polythera-
py, those using medications requiring variable
dosages (e.g., anticoagulants), or patients with phys-
ical limitations which prevent or complicate the cor-
rect use of medications (e.g., visually impaired peo-
ple). There are also systems with administration sig-
nalling devices which remind patients when it is nec-
essary to take a medication. All individual dosage
systems are presently only directed towards the dis-
pensation of medications for oral administration. The
role of the pharmacist providing such a service is to: 
 draft protocols for preparing different formula-
tion of medication;
 choose patients who may significantly benefit
from the application of SIMP;
 establish correct medication application pro-
grammes for a patient within the SIMP frame-
work; 
 control an individual SIMP designed by qualified
personnel for an individual patient, including the
design of an information leaflet;
 release every prepared set to be dispensed to the
patient.
Implementing such a system requires agree-
ment with medication producers and recognizing sit-
uations in which the repackaging of medication from
the original packaging is inadvisable/impossible due
to a potential decline in stability or suitability for use.
In some countries, forms of collective packaging are
prepared specifically for use in repackaging.
The tasks of supervising bodies include prepar-
ing or adopting other countriesí guidelines for indi-
vidual medication packaging and specifying active
substances or medicinal products which, due to pos-
sible changes in durability, cannot be covered by
SIMP. Procedures that minimize errors which occur
in the course of placing doses of medicinal products
into packaging should be implemented.
I.3. Educating patients in community pharmacies
Services provided by pharmacies should also
include programmes for educating patients. These
tools for raising health awareness among patients and
influencing attitudes towards health are commonly
applied in projects related to public health. Education
is also strictly connected to the elimination of so-
called functional illiteracy in areas related to medicine
(health illiteracy). Pharmacists may provide individual
forms of education not only to patients under care, but
also to patients who use specified drug forms or med-
ical devices, or suffer from specified illnesses.
Medication categories that should be taken into
account in planning individualized, extended educa-
tion programmes concerning the use of special med-
ications include: eye drops, inhaled medications,
medications for subcutaneous administration,
lyophilizates and therapeutic systems (e.g., transder-
mal systems). Every time a pharmacist dispenses a
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particular medication, he/she has to give the patient
detailed instructions of how to use the given medic-
inal product/medical device, together with a demon-
stration. This may be conducted using the actual
preparation being purchased by the patient or an
instructional product containing inert substance.
Qualified personnel should also ensure that
individualized leaflets are given to patients, espe-
cially when a patient receives medication for the
first time. When providing individualized informa-
tion about medication (which is separate from the
Patient Information Leaflet, PIL), pharmacists
should include the reasons for prescribing the med-
ication (indications for use), the expected effect and
methods of assessing a given preparationís effec-
tiveness, individual dosage programmes (times of
day, hours), food that should be avoided during
medication use and warnings concerning its use that
the patient should be aware of (e.g., dangers related
to driving motor vehicles).
Offering extended education and information
about medications in community pharmacies requires
ensuring access to electronic systems enabling the
storage and distribution of leaflets prepared for
patients in electronic form, as well as using modern
forms of communication with patients, e.g., the
Internet, mobile phones. Another essentiality is the
access to updated databases including leaflets about
medications, SPC and to systems simplifying the
preparation of leaflets, e.g., coupled with sale systems.
Pharmacists also can and should get involved
in group training programmes for patients, e.g., asth-
ma schools or diabetes workshops. Pharmacists pro-
viding health education may organize short meet-
ings with patients during which a pharmacistís
unique knowledge of a medication should be used to
teach patients how to correctly use medications,
including not only how they should be taken but also
their preparation or storage.
I.4. Preparing medications in pharmacies
The Council of Europe Resolution of January
2011 on quality and safety assurance requirements
for medicinal products prepared in pharmacies for
the special needs of patients [CM/ResAP (2011)1]
identifies officinal and magistral drugs as being of
added value, which means that in pharmacies
(including hospital pharmacies) only medications
which are not accessible in ready form on the mar-
ket should be prepared. This concerns, inter alia,
ophthalmic drugs, preparations for parenteral nutri-
tion and cytostatic drugs.
In pharmacies, a reconstitution should also be
introduced. In the case of medicinal products requir-
ing preparation directly before administration, e.g.,
suspensions containing antibiotics or eye drops, a
pharmacist should make sure that the medication
will be correctly prepared by a patient or, alterna-
tively, the pharmacist should prepare medication in
a form ensuring its correct use. It is advisable to dis-
pense a medication that is ready to be taken/admin-
istered by patients, e.g., by dissolving the
lyophilizate of an active ingredient or preparing a
suspension of lyophilizate. Introducing methods of
this type will limit the number of situations of incor-
rect preparation of medication by a patient, e.g.,
using the incorrect solvent or inappropriate amount
of solvent, thus leading to unintended increase/
decrease in the dose.
I.5. Programmes of pharmaceutical care
I.5.1. Pharmaceutical care for the elderly
The geriatric population (people over 65 years
old) requires special attention and the involvement of
medical personnel, particularly because of two phe-
nomena which commonly occur in this group of peo-
ple: multidisease and polypharmacy. In pharmaceuti-
cal care programmes for this group, attention shall be
paid to problems related to incorrect medication use
and instances of noncompliance with therapeutic rec-
ommendations or polytherapy, among others.
 Noncompliance with therapeutic recommenda-
tions ñ in the case of elderly persons, irregular
medication use often results from unintended
reasons, including forgetting, unintentional dis-
continuation, or refusal to buy medications, e.g.
for financial reasons. Monitoring such circum-
stances and eliminating them could be achieved
using individual medication packaging systems.
However, it is also necessary to control the fac-
tors leading to the intended discontinuation of
drugs which include, above all, drug related
problems (e.g., adverse effects). The role of phar-
macists from generally accessible pharmacies is
thus to design systematic mechanisms of detec-
tion and elimination of the occurrence of non-
compliance with therapeutic recommendations.
 Polytherapy ñ this often leads to iatrogenic dis-
eases, which, in turn, result in the use of subse-
quent medicinal products, often forcing patients to
take multiple (up to a dozen or so) doses of med-
ication per day. The role of pharmacists from com-
munity pharmacies is to conduct a detailed analy-
sis of the pharmacotherapy of patients using poly-
therapy, and the tools which may be applied for
this purpose are regular Medication Reviews. In
essence, programmes of reduction of the polyther-
apy occurrence constitute a combination or devel-
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opment of other services described in this docu-
ment, such as MRs, individual medication packag-
ing systems, systems to create individual leaflets
for patients and group patient education systems.
I.5.2. Pharmaceutical care for chronically ill patients
Providing comprehensive pharmaceutical care
should be obligatory in the case of all patients,
regardless of their age, using medications chronical-
ly and requiring periodic control, in order to adjust
pharmacotherapy to changing symptoms and dis-
ease indicators. This is because pharmaceutical care
is a complex procedure, in the course of which a
pharmacist detects and solves drug related prob-
lems, educates the patient and cooperates with other
members of the medical team in a way which
ensures improvement in the patientís quality of life.
Pharmacists providing pharmaceutical care are
qualified to supervise the effectiveness of applied
pharmacotherapy. Pharmacists should have the
opportunity to keep their own records and to access
medical records in order to supervise a patientís
pharmacotherapy correctly (effectively). Pharmaceu-
tical records should be treated the same as medical
records (in a legal sense) and should constitute a pos-
sible basis for control in situations when pharmaceu-
tical care will be financed from public funds.
Pharmaceutical care should in the future become one
of the reimbursed services offered by pharmacist in a
pharmacy. The pharmacist would sign a contract
with the National Health Fund (NFZ), drawn up on
the basis of the contract of a physician of primary
health care (POZ). Patients may get an opportunity to
choose their own pharmacist in the same way they
choose a POZ physician, nurse, and midwife. The
role of the pharmacist would be to monitor pharma-
cotherapy and contact other members of the medical
team providing care for the patient.
I.6. Monitoring on safety and effectiveness of dis-
pensing medications without prescription
Pharmaceutical counselling when choosing
over-the-counter (OTC) medication is an area in
which pharmacists have a chance to apply their
knowledge for ensuring correct medication use.
However, it is essential to prepare detailed proce-
dure standards setting out rules for pharmacistsí
conduct in relation to OTC medication dispensation.
It may be also useful to prepare Standard Operating
Procedures (SOPs) for chosen drug categories or ail-
ments patients complain about.
Self-treatment counselling provided by a phar-
macist should also include an interview to determine
whether any medications bought without prescrip-
tion outside the pharmacy were used. The pharma-
cist, in applying such knowledge, may thereby pre-
vent situations of abuse or incorrect use of these
medications. He/she should also warn the patient that
sometimes purchasing medications without specialist
advice that can be provided only by pharmacist or
physician may be unsuitable or even dangerous. 
I.7. Control of diet supplements use
Diet supplements are products which should be
used only in order to correct deficiencies of certain
minerals and vitamins in a diet. Unfortunately, aggres-
sive promotional and advertising campaigns of certain
diet supplements producers result in people buying an
increasing number of products in order to benefit from
suggested health condition improvements, not only to
correct natural deficiencies. Pharmacists should pro-
vide advice regarding the choice of diet supplements,
especially for people with chronic illnesses. The pres-
ent knowledge of interactions between these sub-
stances and medications is insufficient. The presence
of diet supplements in a pharmacyís assortment
should oblige a pharmacist to duly inform and provide
specialist advice to the patient in order to prevent
duplication or overdose of substances. The aim should
be to ensure that, based on pharmacistsí unique
knowledge and competencies, the quality of diet sup-
plements available in pharmacies is high and benefi-
cial for society at large, as opposed to what non-phar-
macy outlets offer their customers. Pharmacists
should explain to patients the difference between
medicinal products and diet supplements.
I.8. Prophylaxis and health promotion
The aim of prophylaxis and health promotion
activities is to produce changes in the health behav-
ior of patients, both among healthy persons who
rarely visit the pharmacy and chronically ill persons,
for whom behaviors of these kind may contribute to
efforts to fight disease and an improvement in their
quality of life. Prophylactic actions in pharmacies
should be conducted in certain areas or time inter-
vals. Attention shall be paid to preparing activities
in pharmacies in accordance with areas of pharma-
cistsí interests, i.e., directly related to the promotion
of correct medication use or limiting its use to situ-
ations of necessity. Prophylaxis and health promo-
tion programmes, introduced in generally accessible
pharmacies, may include, inter alia.:
 smoking cessation programmes/nicotine replace-
ment therapy counselling (NTZ);
 programmes of early disease detection (screen-
ing programmes): detecting hypertension, dia-
betes, hyperlipidemia, metabolic syndrome;
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 prophylaxis of obesity;
 protective vaccinations;
 promoting healthy lifestyles (diet, physical activ-
ity).
It is a mistake to omit the role of pharmacist in
programmes of early detection of chronic illnesses,
since it is the pharmacist that often is the first person
in health care system with whom an ill person comes
into contact. Pharmacists should be prepared to
identify a situation of chronic self-treatment without
consulting a physician or seeing a diagnosis. The list
of illnesses that may be identified with pharmacistsí
participation should include hypertension, diabetes,
metabolic syndrome, hyperlipidemia, risk factors
for neoplastic diseases, venous thromboembolic dis-
ease, peptic ulcer disease and respiratory system dis-
eases evidenced by a persistent cough.
The role the of pharmacist is to identify
patients whose symptoms may indicate chronic con-
ditions; the pharmacistís task is not to conduct stud-
ies whose results may constitute the basis for further
investigation by a physician but, above all, to draw
the patientís attention to the possibility that some
symptoms may be related to serious conditions. It is
important to indicate the conditions whereby
informing a patient may contribute to the identifica-
tion of disease at early stage and prevent, or at least
considerably delay, exhibiting its most extreme con-
sequences. The pharmacistís role is therefore to con-
duct a proper interview when the patient purchases
OTC drugs ñ this concerns e.g., drugs from the pro-
ton-pump inhibitors group, non-steroidal anti-
inflammatory drugs and antitussives/expectorants.
Meeting with pharmacists in the course of screening
programmes should also result in passing informa-
tion to a patient for whom symptoms indicating a
health problem were identified. The information
should include factors such as which specialist a
patient should turn to, whether a referral from a gen-
eral practitioner is necessary and where to find
information about specialist outpatient clinics.
The role of institutions and scientific associa-
tions is to design appropriate guidelines and proce-
dural standards, as well as to indicate in cooperation
with medical organizations the situations in which it
is possible, with a properly conducted interview, to
draw a patientís attention to health problems and the
improvement of health attitudes.
I.9. Pharmacists writing prescriptions
In some countries, it is possible for pharmacists
to prescribe medications of the prescription only dis-
pensing category. Introducing this option increases the
accessibility of medicinal products for patients but
requires a clearly specified scope of responsibility and
competences for all professional groups prescribing
medications. The UK may serve as the model country
for pharmacists providing this type of service. The
writing of prescriptions by pharmacists requires:
 specifying the pharmacistís competences and
methods of controlling them through the creation
of a training system for pharmacists authorized to
write prescriptions;
 the preparation of guidelines including, inter alia,
a descriptions of situations in which a pharmacist
has no right to write a prescription and a list of
categories of drugs which canít be prescribed by
a pharmacist;
 the creation of a system for monitoring the issuing
and dispensing of such prescriptions, as well as
cooperating with the attending physician of
patients for whom pharmacist issues a prescription.
Extending the group of professions authorized
to prescribe medications enables significant savings
in a health system, particularly if the newly author-
ized person is a pharmacist. However, in order to
avoid prescribing a medicinal product for the purpose
of increasing distribution, it is essential to create a
system to monitor the substantive validity of issuing
prescriptions by pharmacists. Writing prescriptions
requires access to medical records for the authorized
pharmacists in order to read diagnoses and complete
records with information on the prescribed medica-
tions. Pharmacists must also be able to directly con-
sult a physician to design the best possible treatment.
I.10. Certification of pharmacists and accredita-
tion of pharmacies to provide additional services
Systems of quality management in the area of
pharmaceutical care should ensure that the patient
achieves the maximum possible therapeutic advan-
tage and the necessary competences as well as the
practical experience of pharmacists in work with
individual patients should be specified and periodi-
cally verified. An important element in ensuring the
quality of services are norms, procedures, and accu-
rate records enabling the systematic assessment of
progress and treatment results for individual
patients, as well as registration and self-assessments
of the professional activity of pharmacists.
Pharmacists should aim at creating a system
which would ensure the provision of high quality
services. In the framework of this system, it is neces-
sary to establish institutions/teams confirming per-
sonnel qualifications and ensuring the appropriate
quality of structures and processes related to phar-
maceutical care. Within a system of this kind it is
advisable to design frameworks for the certification
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of pharmacists and accreditation of pharmacies pro-
viding pharmaceutical care and offering an extended
scope of pharmaceutical services from this area. 
PART II. Actions to increase the role of pharma-
cists in the health system
A health care system is a complicated mecha-
nism whose aim is to ensure access to programmes
and technology which enable every member of soci-
ety to regain, improve, or maintain their health. For
every type of profession functioning within this sys-
tem, tasks should be specified and areas of responsi-
bility indicated. Part II of this document therefore
includes a list of areas in a health system in which it
is possible and desirable to employ pharmacistsí
knowledge. Extending the scope of responsibility
will contribute not only to an increase in profession-
al satisfaction among pharmacists from generally
accessible pharmacies and raise the prestige of this
professional group, but may also contribute to future
improvements to the health indicators of society and
the rational employment of financial means in areas
related to pharmacotherapy.
II.1. Involving pharmacists in actions associated
with the reimbursement policy
At the present moment, the role of pharmacists
in the reimbursement system is limited to involve-
ment in the process of medication distribution in
generally accessible pharmacies. However, in the
course of designing the reimbursement system sev-
eral areas were created to which pharmacists may
and should contribute using their specialist knowl-
edge of medicinal products. Therefore, within the
system it is necessary to create mechanisms encour-
aging pharmacists to take up activities in such areas
of the health system in which they can employ their
knowledge and skills acquired during their educa-
tion. Pharmacists can be responsible for:
 negotiations with pharmaceutical companies at
the Ministry of Health Economic Commission;
 rationalizing activities within the framework of
the NFZ (National Health Fund);
 health technology assessments (HTA) within the
framework and by order of the Agency for
Health Technology Assessment and Tariffs
(AOTMiT);
 being active in the Transparency Council of
AOTMiT;
 cooperating with pharmaceutical companies in
conducting HTAs.
It is noteworthy that pharmacists possess
unique knowledge of the research and development,
and manufacture of medicinal products. However, it
is essential to create mechanisms in the education
system for pharmacists to encourage them to acquire
knowledge that blends economy and pharmacy,
which would be exceptionally useful in areas relat-
ed to medication reimbursement. Taking into
account the education of pharmacists, their partici-
pation in the decision making processes for reim-
bursement seems obvious since pharmacists can, in
reference to drug technologies:
 determine their clinical effectiveness;
 establish cost components related to their eco-
nomic assessment;
 estimate cost-effectiveness indicators;
 determine the consequences of reimbursement
for drug technologies.
II.2. Including pharmacists in medical teams car-
ing for patients with selected illnesses ñ diabetics,
asthmatics
It is essential to work out a model for sharing
responsibility for the correct pharmacotherapy of a
patient between physicians prescribing medications
and pharmacists monitoring their application. A basic
task for a pharmacist, as a medical team member, is
to take on partial responsibility for conducting effec-
tive, safe, and at the same time cost-effective phar-
macotherapy. Performing this task takes place not
only through direct cooperation with the patient and
his education, but also through sharing knowledge
and experience with representatives of other medical
professions. In the guidelines of the Polish Diabetes
Association, a pharmacist wasnít mentioned as a
member of a diabetes care team. Unfortunately, in
many documents of these kind, the role of the phar-
macist as a potential educator of a patient is left out.
II.3. Increasing the involvement of pharmacists in
monitoring the adverse effects of medications
The provisions of Polish law impose on phar-
macists an obligation to give information to relevant
authorities on adverse effects reported by patients.
Unfortunately, at the present moment, as statistics
kept by the Office for Registration of Medicinal
Products, Medical Devices and Biocidal Products
show, the number of reports passed on by pharmacists
is very small. This may be caused by a lack of knowl-
edge on the specialist personnelís side regarding the
purposefullness and significance of this kind of infor-
mation and its relation to monitoring the safety of
pharmacotherapy. Pharmacists should considerably
increase their involvement in sending reports on
adverse effects, particularly due to the fact that, under
new provisions of EU law from July 2012, patients
can also directly pass information on observed
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adverse effects of drugs they use to monitoring insti-
tutions. Increasing pharmacistsí involvement in mon-
itoring adverse effects may help verify and substanti-
ate reports given directly by patients. Pharmacists
should pass on reports using the so-called ìyellow
cardsî every time patients report suspected adverse
effects, even if the effect was already mentioned in
documents (SPC). Adverse effects are one of the most
commonly occurring drug related problems. Their
detection in the course of pharmaceutical care should
always result in sending a relevant card.
It is worth paying attention here to a recommen-
dation to report to medication producers instances of
using medications among high risk groups for which
proper research on safety and effectiveness wasnít
conducted, such as newborns, infants, children, preg-
nant women and people with organ failure related to
the metabolism process and drug excretion.
II.4. Increasing pharmacistsí awareness of and
involvement in studies on pharmaceutical practice
Practicing medicine is often coupled with sci-
entific research. In university hospitals, as well as
others, conducting therapy is often combined with
research. On the other hand, practicing pharmacy in
Poland is extremely rarely connected with conduct-
ing scientific studies, although ñ as examples of
other countries show ñ such studies in the area of
pharmaceutical practice may significantly contribute
to improvements in the safety and effectiveness of
pharmacotherapy. In research within the area of
pharmaceutical practice, for the most part, the
methodology of qualitative research applied in social
sciences (sociology, anthropology, psychology) is
employed. Chamber of Pharmacists and pharmacist
organizations should promote the participation of
pharmacists in studies of this kind and support them
financially through awards and grants, particularly
for individual pharmacists from generally accessible
pharmacies who wish to pursue such activity. Polish
research centres conducting such research without
practical support or participation from pharmacists
sometimes encounter serious difficulties or arenít
even able to carry out research within the area of
pharmaceutical practice. Conducting regular studies
on pharmaceutical practice in generally accessible
pharmacies enables working out new types of phar-
maceutical services adapted to Polish conditions.
Attention should be paid to several elements
that are significant from the point of view of
researching pharmaceutical practice in Poland:
 all around the world, the assessment of medication
use in out-patient and in-patient health care is per-
formed on the basis of health data made available
by health care units, including, inter alia, data on
drug application; however, Article 103 of the
Pharmaceutical Law Act practically hinders obtain-
ing data from pharmacies for the needs of studies
conducted by scientific units, so assessment of the
effectiveness of changes put into practice is possible
only due to conducted clinical trials, in the course of
which new types of services are introduced and test-
ed directly in pharmacies. In the case of studies con-
ducted with peopleís participation, the necessity of
obtaining the approval of the relevant bioethical
commission should be taken into account;
 changes to pharmaceutical practice require fund-
ing, part of which may be obtained through funds
for conducting research, including European funds
ñ a significant part of funding competitions often
involves giving information on studies carried out
to the public. This may cause problems related to
the prohibition of advertising pharmaciesí activity;
 studies conducted for patients require their con-
sent, and the process of collecting and storing
personal data or sensitive data containing infor-
mation relating to a patientís health condition
must be in accordance with the provisions on
personal data protection.
PART III. Tasks for state institutions and public
organizations
Tasks for advisory teams, chamber of pharmacist,
and scientific associations include designing guidelines
and standards of procedure to ensure that pharmacies
deliver high quality services. In preparing binding doc-
uments, the positions of the World Health
Organization (WHO), the International Pharmaceutical
Federation (FIP), and the Pharmaceutical Group of the
European Union (PGEU) which specify the role of
pharmacists and tasks for them in health care systems
may be particularly helpful.
It is necessary to create a system of guidelines
and recommendations concerning drug forms or
groups, which should include extended education
for pharmacists. With regard to actions taken in
pharmacies, it is possible to establish guidelines
concerning the treatment of chosen chronic diseases
and adjust them to the specific needs emanating
from pharmacistsí work with patients, paying par-
ticular regard to the professional competences of
pharmacists. Designing guidelines will help simpli-
fy work with individual patients.
III.1. New tasks for chosen state institutions
III.1.1. Tasks for Pharmaceutical Inspectorate
 Helping public scientific and research institu-
tions to conduct studies in the area of pharma-
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ceutical practice through jointly establishing pro-
cedural rules for conducting scientific and
research activities in the environment of general-
ly accessible pharmacies, paying particular
regard to the applicable provisions of law.
 Supporting actions aimed at creating a system of
certification for pharmacists and accreditation
for pharmacies in the scope of providing addi-
tional services related to pharmaceutical care in
community pharmacies.
 Participation through its representatives in
designing guidelines and procedural standards
for different types of pharmaceutical services
related to pharmaceutical care ñ Pharmaceutical
Inspectorate (IF) employeesí knowledge may
help in drafting documents in which the quality
of services exceeds minimal legal requirements.
 Supporting activities aimed at making changes to
the law in order to widen the scope of services
provided in pharmacies and improve their quality:
● proposing changes to applicable legal provi-
sions which would support actions aimed at
improving the quality of pharmaceutical serv-
ices, including changes to the regulations of
the Minister of Health concerning conditions
for operating a pharmacy, among others;
● assessing changes aimed at increasing the com-
petences of skilled pharmacy employees pro-
posed by other organizations and institutions;
● indicating areas where change is required and
taking active participation in work on changes
to the law whose purpose is to extend the
scope of pharmaceutical services and improve
their quality.
 Including information on services related to
pharmaceutical care in training programmes, and
regular meetings of pharmaceutical inspectors
performing control of generally accessible phar-
macies, who should be acquainted with:
● rules for conducting studies related to pharma-
ceutical practice;
● modern services provided in community phar-
macies in developed countries;
● systems of implementation and quality control
in community pharmacies;
● guidelines and recommendations of pharma-
ceutical and medical organizations for the role
of pharmacist in contemporary health systems
(e.g., FIP, WHO).
 Participation of IF representatives in the work of
Polish scientific associations and pharmacist organ-
izations on improving professional practice. The
greater the IFís knowledge of the real problems
experienced within in the pharmaceutical services
market, the easier it will be to draft documents
which will help improve pharmaceutical practice.
 Permanent participation of IF representatives in
the work of international organizations acting
towards improving pharmaceutical practice, i.e.,
the Pharmaceutical Group of the European Union
and the Committee of experts on quality and safe-
ty standards in pharmaceutical practices and phar-
maceutical care within the Council of Europe.
 Supporting the involvement of Polish researchers
in international research related to pharmaceuti-
cal practice through working out a permanent
model of cooperation with scientific and research
units functioning at public higher schools.
 The active participation of IF representatives in
actions aimed at making amendments to the law
to improve pharmaceutical practice.
III.1.2. Tasks for the Ministry of Health
 Proposing amendments to the law which would
promote actions aimed at improving quality in
the area of pharmaceutical practice, enabling
future financing for additional pharmaceutical
services from public funds.
 Including pharmacist representatives in teams
permanently and periodically cooperating with
the Ministry for the purpose of improving the
national medication and reimbursement policy.
 Promoting quality in areas related to pharmaceu-
tical practice.
III.2. New tasks for public organizations in phar-
macy ñ chamber of pharmacists, scientific associa-
tions, foundations, and others
III.2.1. Tasks for Chamber of Pharmacists
 Cooperation with and supporting the activity of
scientific and research centres in the scope of
conducting studies on professional practice
through taking common initiatives, funding
rewards for scientists from community pharma-
cies and promoting and supporting cooperation
initiatives between businesses from the pharma-
ceutical practice sector and scientific institutions;
 Promoting the quality of pharmaceutical services
provided in generally accessible pharmacies, cre-
ating teams in pharmacies and pharmacy organi-
zations whose aim is to improve the quality of
pharmaceutical services and creating a system of
accreditation of pharmacies and certification of
pharmacists;
 Designing guidelines and recommendations for
services provided in community pharmacies;
 Preparing organizational and legal strategies for
the development of pharmaceutical practice;
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 Active seeking of funds for supporting activities
within the area of pharmaceutical practice;
 Appointing a team (including members of organ-
izations and scientific institutions) to prepare
reports assessing the cost-effectiveness of addi-
tional services provided in pharmacies, which
will enable them to be included in the list of serv-
ices financed from public funds;
 Appointing a permanent representative at the
Sejm (lower house of Parliament) of the
Republic of Poland to lobby for the improvement
of pharmaceutical practice;
 Working out a model for rewarding pharmacists
from community pharmacies who conduct scien-
tific and research activity or participate in it ñ
e.g., increasing the number of educational points
for participation in scientific research and con-
ferences, as well as scientific publications;
 Working out a model of cooperation and sharing
responsibility for pharmacotherapy between
physicians and pharmacists;
 Conducting informational campaigns directed
partly towards representatives of other medical
professions and partly towards patients, with the
purpose of providing information on the role of
modern pharmacists in a health care system and
presenting their competences and knowledge
which should be used in actions for improving
the health of society.
III.2.2. Tasks for scientific organizations and associ-
ations
 Designing guidelines and standards of procedure
which will ensure that quality standards of addi-
tional pharmaceutical services provided in com-
munity pharmacies are maintained;
 Preparing research development strategies in the
area of pharmaceutical practice, promoting the
activities of scientific institutions engaged in
studies on pharmaceutical practice, providing
financial support to initiatives in this area, and
initiating actions aimed at increasing the involve-
ment of pharmacists from community pharma-
cies in research on pharmaceutical practice;
 Promoting and helping to publicize research
results from the area of pharmaceutical practice ñ
subsidizing attendance at scientific conferences
and other forms of popularizing the results.
III.3. New state and/or public teams and bodies
 The creation of a team engaged in providing
accreditation for pharmacies and certification for
pharmacists that provide additional pharmaceuti-
cal services in community pharmacies;
 The creation of a team engaged in finding legisla-
tive solutions related to pharmaceutical practice.
III.4. Development of permanent cooperative rela-
tionships between state institutions, public organi-
zations, and private business representatives
 Preparing documents specifying a common
framework of actions for the state and private
institutions;
 Devising a list of institutions, organizations,
associations, and foundations engaged in differ-
ent aspects of pharmaceutical practice.
III.5. Changes to the law
Changes in the area of pharmaceutical practice
require amendments to existing implementing provi-
sions. New legal provisions should take into account:
 keeping records of actions related to pharmaceu-
tical care in community pharmacies;
 functional adjustments of pharmacies to the new
professional activity of pharmacists;
 financing additional services in pharmacies from
public funds;
 participation of pharmacists in actions for public
health;
 employing resources from savings related to the
reimbursement of medicinal products to conduct
research related to pharmaceutical practice;
 actions related to the accreditation and certifica-
tion of pharmacies and pharmacists;
 changes related to awarding educational points
for scientific and research activity and publica-
tion of their results.
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